Protalix BioTherapeutics, Inc.
PLXAs of the close on Sep 25, 2026
Price
$2.72
Market cap
$219M
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Protalix BioTherapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Dec 23, 2025. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| HARBOUR INVESTMENT MANAGEMENT LLC | 2026-03-31 | 10,100 | Not shown | SEC filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2026-03-31 | 159,311 | Not shown | SEC filing |
| Smartleaf Asset Management LLC | 2026-03-31 | 25,975 | Not shown | SEC filing |
| DEUTSCHE BANK AG\ | 2026-03-31 | 74,985 | Not shown | SEC filing |
| COMMONWEALTH EQUITY SERVICES, LLC | 2026-03-31 | 19,461 | Not shown | SEC filing |
| Sterling Capital Management LLC | 2026-03-31 | 453 | Not shown | SEC filing |
| VOYA INVESTMENT MANAGEMENT LLC | 2026-03-31 | 11,494 | Not shown | SEC filing |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 11,720 | Not shown | SEC filing |
| Cascade Financial Partners, LLC | 2026-03-31 | 12,000 | Not shown | SEC filing |
| Kestra Advisory Services, LLC | 2026-03-31 | 10,000 | Not shown | SEC filing |
| ProShare Advisors LLC | 2026-03-31 | 10,589 | Not shown | SEC filing |
| LAZARD ASSET MANAGEMENT LLC | 2026-03-31 | 86,617 | Not shown | SEC filing |
| ROTHSCHILD INVESTMENT LLC | 2026-03-31 | 15 | Not shown | SEC filing |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2026-03-31 | 19,528 | Not shown | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 12,250 | Not shown | SEC filing |
| SIMPLEX TRADING, LLC | 2026-03-31 | 22,671 | Not shown | SEC filing |
| Phoenix Financial Ltd. | 2026-03-31 | 40,000 | Not shown | SEC filing |
| Equitable Holdings, Inc. | 2026-03-31 | 11,150 | Not shown | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-03-31 | 49,085 | Not shown | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 5,158 | Not shown | SEC filing |
- Each value is checked against Protalix BioTherapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- State of Alaska, Department of Revenue: 21,831 shares reported 2025-12-31; 21,831 shares reported 2026-03-31.
- Diametric Capital, LP: 138,929 shares reported 2025-12-31; 124,195 shares reported 2026-03-31.
- WELLS FARGO & COMPANY/MN: 79,002 shares reported 2025-12-31; 26,522 shares reported 2026-03-31.
- GAMMA Investing LLC: 355 shares reported 2025-12-31; 479 shares reported 2026-03-31.
- NORTHERN TRUST CORP: 865,708 shares reported 2025-12-31; 885,448 shares reported 2026-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 830,054 shares reported 2025-12-31; 865,298 shares reported 2026-03-31.
- Opaleye Management Inc.: 2,478,176 shares reported 2025-12-31; 340,000 shares reported 2026-03-31.
- UBS Group AG: 262,520 shares reported 2025-12-31; 265,535 shares reported 2026-03-31.
- BNP PARIBAS FINANCIAL MARKETS: 17,021 shares reported 2025-12-31; 17,343 shares reported 2026-03-31.
- EVERGREEN CAPITAL MANAGEMENT LLC: 171,338 shares reported 2025-12-31; 171,338 shares reported 2026-03-31.
- NEW YORK STATE COMMON RETIREMENT FUND: 31,100 shares reported 2025-12-31; 31,100 shares reported 2026-03-31.
- LPL Financial LLC: 10,291 shares reported 2025-12-31; 10,291 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
81 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Protalix BioTherapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-06-10 · Schwartz Aharon: Larger than 11 of the 12 other insider purchases of Common Stock on file. SEC filing
- 2021-06-03 · Oren Dan: Larger than 107 of the 111 other insider sales of Common Stock on file. SEC filing
- 2016-12-02 · Camber Capital Management LLC: Larger than 109 of the 111 other insider sales of Common Stock on file. SEC filing
- 2015-10-19 · Camber Capital Management LLC: Larger than all 12 other insider purchases of Common Stock on file. SEC filing
- 2014-08-13 · Bronfeld Zeev: Larger than 110 of the 111 other insider sales of Common Stock on file. SEC filing
- 2014-08-13 · Bio-Cell Ltd: Larger than 110 of the 111 other insider sales of Common Stock on file. SEC filing
- 2012-05-02 · Aviezer David: Larger than 106 of the 111 other insider sales of Common Stock on file. SEC filing
- 2012-05-02 · Shaaltiel Yoseph: Larger than 105 of the 111 other insider sales of Common Stock on file. SEC filing
- 2012-05-02 · Almon Einat Brill: Larger than 102 of the 111 other insider sales of Common Stock on file. SEC filing
- 2010-03-24 · Shaaltiel Yoseph: Larger than 103 of the 111 other insider sales of Common Stock on file. SEC filing
- 2010-03-23 · Shaaltiel Yoseph: Larger than 100 of the 111 other insider sales of Common Stock on file. SEC filing
- 2009-11-12 · Hurvitz Eli: Larger than 108 of the 111 other insider sales of Common Stock on file. SEC filing
- 2009-11-12 · Hurvitz Eli: Larger than 104 of the 111 other insider sales of Common Stock on file. SEC filing
- 2009-10-19 · Aviezer David: Larger than 101 of the 111 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-19 | Bashan Dror · PRESIDENT AND CEO | Common Stock | P — Open market or private purchase | +56,000 | 1.81 | SEC filing |
| 2025-11-18 | Bar-Shalev Amos · Director | Common Stock | S — Open market or private sale | −168 | 1.87 | SEC filing |
| 2025-06-10 | Schwartz Aharon · Director | Common Stock | P — Open market or private purchase | +129,000 | 1.60 | SEC filing |
| 2023-10-19 | Bashan Dror · PRESIDENT AND CEO | Common Stock | P — Open market or private purchase | +48,387 | 1.40 | SEC filing |
| 2023-10-19 | Bashan Dror · PRESIDENT AND CEO | Common Stock | P — Open market or private purchase | +16,129 | 1.41 | SEC filing |
| 2023-01-03 | Schwartz Aharon · Director | Common Stock | P — Open market or private purchase | +110,000 | 1.42 | SEC filing |
| 2022-04-11 | Bashan Dror · President and CEO | Common Stock | P — Open market or private purchase | +68,000 | 1.50 | SEC filing |
| 2021-06-03 | Oren Dan · 10% owner | Common Stock | S — Open market or private sale | −857,506 | 2.25 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-09-03 | Forster Eliot · Director | Stock Options (Right to Buy) | A — Grant, award, or other acquisition | +15,000 | SEC filing |
| 2025-09-03 | Elze Christian · Director | Stock Options (Right to Buy) | A — Grant, award, or other acquisition | +15,000 | SEC filing |
| 2025-09-03 | Elze Christian · Director | Common Stock | A — Grant, award, or other acquisition | +7,500 | SEC filing |
| 2025-09-03 | Bar-Shalev Amos · Director | Common Stock | A — Grant, award, or other acquisition | +7,500 | SEC filing |
| 2025-09-03 | Forster Eliot · Director | Common Stock | A — Grant, award, or other acquisition | +7,500 | SEC filing |
| 2025-09-03 | Schwartz Aharon · Director | Common Stock | A — Grant, award, or other acquisition | +7,500 | SEC filing |
| 2025-09-03 | Ben Zvi Shmuel · Director | Common Stock | A — Grant, award, or other acquisition | +7,500 | SEC filing |
| 2025-09-03 | Bashan Dror · PRESIDENT AND CEO | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +340,000 | SEC filing |
Showing 8 of 25 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2014-10-02 | Bronfeld Zeev · Director | Common Stock | J — Other acquisition or disposition | +324,372 | SEC filing |
| 2014-10-02 | Bronfeld Zeev · Director | Common Stock | J — Other acquisition or disposition | −1,509,948 | SEC filing |
| 2014-09-16 | Bronfeld Zeev · Director | Common Stock | J — Other acquisition or disposition | −8,556,371 | SEC filing |
| 2014-09-16 | Bio-Cell Ltd · 10% owner | Common Stock | J — Other acquisition or disposition | −8,556,371 | SEC filing |
| 2014-09-16 | Bronfeld Zeev · Director | Common Stock | J — Other acquisition or disposition | +1,838,109 | SEC filing |
| 2009-11-12 | Hurvitz Eli · Director | Common Stock | J — Other acquisition or disposition | −4,443,443 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.